Why Viking Therapeutics (VKTX) Is the Biotech Stock with Biggest Upside Potential
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...
Medscape11 天
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute ...
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
The Pharma Letter3 天
GLP-1R gold rush: emerging biotechs set to challenge market leaders
The glucagon-like peptide-1 receptor (GLP-1R) market experienced significant growth in 2023, generating $37.2 billion in ...
From Davids to Goliaths: the GLP-1RA gold rush
There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.
From Davids to Goliaths: the GLP-1R gold rush
There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.
Employee Benefit News8 天Opinion
The major factors that go into the decision to cover GLP-1s
As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two ...